炒鸡屁股
2021-10-22
$fuboTV Inc.(FUBO)$
[得意]
4 Supercharged Growth Stocks Expected to Increase Sales 306% to 658% by 2024<blockquote>4只强劲增长的股票预计到2024年销售额将增长306%至658%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":851099558,"tweetId":"851099558","gmtCreate":1634857398726,"gmtModify":1634857398726,"author":{"id":3532390878444836,"idStr":"3532390878444836","authorId":3532390878444836,"authorIdStr":"3532390878444836","name":"炒鸡屁股","avatar":"https://static.tigerbbs.com/7b09f075ccfdee835c71a50030edddf0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a><span>[得意] </span></p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a><span>[得意] </span></p></body></html>","text":"$fuboTV Inc.(FUBO)$[得意]","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/851099558","repostId":1173506176,"repostType":2,"repost":{"id":"1173506176","kind":"news","pubTimestamp":1634815504,"share":"https://www.laohu8.com/m/news/1173506176?lang=zh_CN&edition=full","pubTime":"2021-10-21 19:25","market":"us","language":"en","title":"4 Supercharged Growth Stocks Expected to Increase Sales 306% to 658% by 2024<blockquote>4只强劲增长的股票预计到2024年销售额将增长306%至658%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1173506176","media":"Motley Fool","summary":"If there's been one standout group of stocks since the end of the Great Recession in 2009, it's grow","content":"<p>If there's been one standout group of stocks since the end of the Great Recession in 2009, it's growth stocks. The combination of historically low lending rates and the Federal Reserve's ongoing quantitative-easing measures have made cheap capital abundant for borrowing purposes.</p><p><blockquote>如果说自2009年大衰退结束以来有一组股票表现出色的话，那就是成长型股票。历史上较低的贷款利率和美联储持续的量化宽松措施相结合，使得廉价资本充足，可用于借贷。</blockquote></p><p> But for some supercharged companies, their growth is just beginning. According to Wall Street's consensus estimate, the following fourgrowth stocks are expected to see their sales climb by 306% to as much as 658% by 2024.</p><p><blockquote>但对于一些增压公司来说，它们的增长才刚刚开始。根据华尔街的普遍估计，到2024年，以下四只成长型股票的销售额预计将增长306%，达到658%。</blockquote></p><p> Redfin: Implied sales growth of 306% by 2024</p><p><blockquote>Redfin：到2024年隐含销售额增长306%</blockquote></p><p> One of the most profound growth stories over the next four years should be technology-driven real estate company <b>Redfin</b>(NASDAQ:RDFN). Last year, the company managed $886 million in revenue. But according to Wall Street, it'll be knocking on the door of $3.6 billion by the time 2024 rolls around.</p><p><blockquote>未来四年最深刻的增长故事之一应该是技术驱动的房地产公司<b>Redfin</b>（纳斯达克：RDFN）。去年，该公司管理的收入为8.86亿美元。但据华尔街报道，到2024年，它将敲开36亿美元的大门。</blockquote></p><p> There's no denying that Redfin has benefited from historically low mortgage rates. But eventually, mortgage rates will rise, and a seemingly spoiled group of prospective buyers will have to cope with rates of 4% or even 5% for 30-year mortgages. Yet even with higher mortgage rates, Redfinlooks poised to succeed.</p><p><blockquote>不可否认，Redfin受益于历史低位的抵押贷款利率。但最终，抵押贷款利率将会上升，一群看似被宠坏的潜在买家将不得不应对4%甚至5%的30年期抵押贷款利率。然而，即使抵押贷款利率较高，Redfin看起来也有望取得成功。</blockquote></p><p> One of the bigger differentiating factors for the company are thecost savings it brings to the table. Traditional real estate companies charge 2.5% to 3% to represent a buyer or seller. Meanwhile, Redfin charges either 1% or 1.5% to act as an agent for its clients.</p><p><blockquote>该公司更大的差异化因素之一是它带来的成本节约。传统房地产公司代表买方或卖方收取2.5%至3%的费用。与此同时，Redfin收取1%或1.5%的费用作为其客户的代理。</blockquote></p><p> This up to 2 percentage-point difference might sound nominally small, but it can easily top $7,000 in cost savings for a seller when we're talking about median-priced existing home sales. As long as economic or pandemic worries persist, the savings Redfin provides should remain in focus.</p><p><blockquote>这种高达2个百分点的差异名义上听起来可能很小，但当我们谈论中位价现房销售时，它可以轻松为卖家节省7,000美元的成本。只要经济或大流行担忧持续存在，Redfin提供的储蓄就应该继续成为焦点。</blockquote></p><p> Furthermore, Redfinprovides personalization that traditional real estate firms don't offer. As an example, Redfin rolled out 3D and virtual tours during the pandemic to keep the hamster on the wheel, so to speak. It also offers its Redfin Now purchasing services in select cities around the country. This service buys homes from sellers in cash, which removes the hassles and haggling that typically accompanies the home-selling process.</p><p><blockquote>此外，Redfin提供了传统房地产公司无法提供的个性化服务。举个例子，Redfin在疫情期间推出了3D和虚拟旅游，可以说是让仓鼠留在方向盘上。它还在全国特定城市提供Redfin Now购买服务。这项服务以现金从卖家那里购买房屋，消除了房屋销售过程中通常伴随的麻烦和讨价还价。</blockquote></p><p> With Redfin heavily reinvesting in its operations, it could be a couple of years before the company turns the corner to recurring profitability. However, sales growth won't demonstrably slow anytime soon.</p><p><blockquote>随着Redfin对其运营进行大量再投资，该公司可能需要几年时间才能实现经常性盈利。然而，销售增长不会很快明显放缓。</blockquote></p><p> Trulieve Cannabis: Implied sales growth of 344% by 2024</p><p><blockquote>Trulieve Cannabis：到2024年隐含销售额增长344%</blockquote></p><p> U.S.-based marijuana stocks are another source of supercharged growth over the coming four years. Perhaps no cannabis stock will deliver more eye-popping nominal sales growth than multistate operator (MSO)<b>Trulieve Cannabis</b>(OTC:TCNNF). Between 2020 and 2024, full-year sales are expected to climb from $521.5 million to about $2.32 billion.</p><p><blockquote>美国大麻股票是未来四年强劲增长的另一个来源。也许没有任何大麻股票能比多州运营商(MSO)带来更令人瞠目结舌的名义销售增长<b>Trulieve大麻</b>（场外交易代码：TCNNF）。2020年至2024年间，全年销售额预计将从5.215亿美元攀升至约23.2亿美元。</blockquote></p><p> To quickly get a big concern out of the way, federal legalization isn't necessary for pot stocks to thrive in the United States. We've witnessed 36 states legalize marijuana in some capacity, and the Justice Department is maintaining a hands-off approach. That's a recipe for high-quality MSOs to succeed.</p><p><blockquote>为了迅速解决一个大问题，联邦合法化并不是大麻股票在美国蓬勃发展的必要条件。我们已经见证了36个州以某种方式将大麻合法化，而司法部正在保持不干涉的态度。这是高质量MSO成功的秘诀。</blockquote></p><p> What's made Trulieve such a unique company is its laser focus on the Florida market. Whereas most MSOs have been stretching themselves thin in an attempt to establish a presence in as many legalized states as possible, Trulieve has opened 100 dispensaries in the Sunshine State. Saturating the medical marijuana-legal Florida market has allowed the company to keep its marketing costs down while effectively building up its brands. It now controls about half the state's dried flower and oils share and has been profitable on a recurring basis for more than three years.</p><p><blockquote>Trulieve之所以成为一家如此独特的公司，是因为它专注于佛罗里达市场。尽管大多数MSO都在竭尽全力试图在尽可能多的合法化州建立业务，但Trulieve已经在阳光州开设了100家药房。医用大麻合法的佛罗里达州市场饱和，使该公司能够在有效建立品牌的同时降低营销成本。它现在控制着该州大约一半的干花和油份额，并且已经连续盈利三年多了。</blockquote></p><p> The next phase of growth for Trulieve will be inorganic. It recently closed an all-stock deal to acquire MSO Harvest Health & Recreation. While Harvest Health had a five-state focus, the allure of this acquisition is Harvest's leading position (15 dispensaries) in its home state of Arizona. The Grand Canyon State legalized recreational weed in November and commenced sales two months later. Trulieve could very well become a runaway leader in Arizona and show shareholders the green.</p><p><blockquote>Trulieve的下一个增长阶段将是无机的。它最近完成了收购MSO Harvest Health&Recreation的全股票交易。虽然Harvest Health专注于五个州，但此次收购的吸引力在于Harvest在其家乡亚利桑那州的领先地位（15家药房）。大峡谷州在11月将娱乐性大麻合法化，并在两个月后开始销售。Trulieve很可能成为亚利桑那州的失控领导者，并向股东展示绿色。</blockquote></p><p> Novavax: Implied sales growth of 658% by 2024</p><p><blockquote>Novavax：到2024年隐含销售额增长658%</blockquote></p><p> It's not surprising to find supercharged growth potential amongbiotech stocks. Going from non-recurring revenue to recurring sales following a first drug approval can lead to a huge percentage surge in sales.</p><p><blockquote>生物科技股的强劲增长潜力并不奇怪。第一个药物获得批准后，从非经常性收入转向经常性销售可能会导致销售额大幅增长。</blockquote></p><p> That's what's expected to happen with <b>Novavax</b>(NASDAQ:NVAX). In 2020, the company recorded almost $476 million in full-year sales. But by 2024, Wall Street's consensus has Novavax pegged for a hair above $3.6 billion in revenue.</p><p><blockquote>这就是预期会发生的事情<b>Novavax</b>（纳斯达克：NVAX）。2020年，该公司全年销售额近4.76亿美元。但华尔街一致认为，到2024年，Novavax的收入将略高于36亿美元。</blockquote></p><p> For the time being, Novavax is a clinical-stage company -- but that seems destined to change.</p><p><blockquote>目前，Novavax是一家处于临床阶段的公司，但这种情况似乎注定会改变。</blockquote></p><p></p><p> The company's leading vaccine candidate is NVX-CoV2373, a treatment for the coronavirus disease 2019 (COVID-19). This vaccine has been through two large-scale, late-stage studies that produced overall vaccine efficacy (VE) of 89.7% (in the U.K.) and 90.4% (in the U.S. and Mexico). While initial VE is just one aspect of the COVID-19 vaccine, Novavax offers a solution that appears to handily outpace <b>Johnson & Johnson</b> and <b>AstraZeneca</b> in initial VE. In other words, it could slide right in as the global No. 3 COVID-19 vaccine if granted emergency-use authorization.</p><p><blockquote>该公司领先的候选疫苗是NVX-CoV2373，一种治疗冠状病毒疾病2019（COVID-19）的药物。该疫苗已经通过了两项大规模的后期研究，总体疫苗效力(VE)分别为89.7%（在英国）和90.4%（在美国和墨西哥）。虽然初始VE只是COVID-19疫苗的一个方面，但Novavax提供的解决方案似乎可以轻松超越<b>强生公司</b>和<b>阿斯利康</b>在初始VE中。换句话说，如果获得紧急使用授权，它可能会成为全球第三大COVID-19疫苗。</blockquote></p><p> Additionally, Novavax could set itself apart from the competition by producing combination vaccines, such as COVID-19 and influenza. The company's vaccine-development platform is designed in such a way that it can potentially beat other large drugmakers to market with combination vaccinations or variant-specific boosters.</p><p><blockquote>此外，Novavax可以通过生产COVID-19和流感等联合疫苗在竞争中脱颖而出。该公司的疫苗开发平台的设计方式是，它有可能击败其他大型制药商，将联合疫苗或变异特异性加强剂推向市场。</blockquote></p><p> Among COVID-19 stocks, Novavax remains the most intriguing, in my view.</p><p><blockquote>在我看来，在COVID-19股票中，Novavax仍然是最有趣的。</blockquote></p><p> fuboTV: Implied sales growth of 582% by 2024</p><p><blockquote>fuboTV：到2024年隐含销售额增长582%</blockquote></p><p> The fourth and final supercharged growth stock is streaming-television provider <b>fuboTV</b>(NYSE:FUBO). After the company delivered $261.5 million in full-year sales in 2020, Wall Street is expecting sales to increase to around $1.78 billion in 2024. That's a cool 582% improvement.</p><p><blockquote>第四只也是最后一只强劲增长的股票是流媒体电视提供商<b>富波电视</b>（纽约证券交易所代码：FUBO）。在该公司2020年全年销售额达到2.615亿美元后，华尔街预计2024年销售额将增至17.8亿美元左右。这是一个很酷的582%的改进。</blockquote></p><p> FuboTV is aiming to capitalize on consumers' distaste of traditional cable, satellite, and telcoTV. A report from NScreen Media shows that over 21 million fewer households had one of these traditional content services in the first quarter of 2021, compared to the same quarter four years earlier. At the same time, the number of households without a traditional cable, satellite, or telcoTV has more than tripled between 2014 and Q1 2021. People are clearly dissatisfied with the lack of choice from traditional cable and satellite providers, and they're unhappy with the high service costs.</p><p><blockquote>FuboTV的目标是利用消费者对传统有线、卫星和电信电视的厌恶。NScreen Media的一份报告显示，与四年前的同一季度相比，2021年第一季度拥有这些传统内容服务的家庭减少了2100多万户。与此同时，2014年至Q1 2021年间，没有传统有线电视、卫星电视或电信电视的家庭数量增加了两倍多。人们显然对传统有线电视和卫星电视提供商缺乏选择感到不满，也对高昂的服务成本感到不满。</blockquote></p><p> For fuboTV, it's all about appealing to consumers who want streamable, live sporting events. Although it offers news and entertainment content, too, the company's core customer, for the moment, is a sports fanatic who wants to cut their content costs. As of June, the company had 682,000 subscribers, which is more than double what it had last year, but still represents a very small figure.</p><p><blockquote>对于fuboTV来说，这一切都是为了吸引想要流媒体直播体育赛事的消费者。尽管它也提供新闻和娱乐内容，但该公司目前的核心客户是希望削减内容成本的体育迷。截至6月，该公司拥有682,000名订户，是去年的两倍多，但仍是一个非常小的数字。</blockquote></p><p> The big question for fuboTV is what'll allow it to separate from the competition. The answer to that question might be sports betting. The company has recently been granted mobile sports-betting licenses in a handful of states, which could provide a tangible lure to the platform.</p><p><blockquote>对于fuboTV来说，最大的问题是什么能让它从竞争中脱颖而出。这个问题的答案可能是体育博彩。该公司最近在几个州获得了移动体育博彩许可证，这可能会给该平台带来切实的吸引力。</blockquote></p><p> For now, fuboTV is losing money hand over fist as it attempts to build up its brand. But if it can find a truly differentiating factor in the streaming space, it could offer long-term appeal.</p><p><blockquote>目前，fuboTV在试图建立自己的品牌时正在大幅亏损。但如果它能在流媒体领域找到真正的差异化因素，它可能会提供长期吸引力。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Supercharged Growth Stocks Expected to Increase Sales 306% to 658% by 2024<blockquote>4只强劲增长的股票预计到2024年销售额将增长306%至658%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Supercharged Growth Stocks Expected to Increase Sales 306% to 658% by 2024<blockquote>4只强劲增长的股票预计到2024年销售额将增长306%至658%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-10-21 19:25</span>\n</p>\n</h4>\n</header>\n<article>\n<p>If there's been one standout group of stocks since the end of the Great Recession in 2009, it's growth stocks. The combination of historically low lending rates and the Federal Reserve's ongoing quantitative-easing measures have made cheap capital abundant for borrowing purposes.</p><p><blockquote>如果说自2009年大衰退结束以来有一组股票表现出色的话，那就是成长型股票。历史上较低的贷款利率和美联储持续的量化宽松措施相结合，使得廉价资本充足，可用于借贷。</blockquote></p><p> But for some supercharged companies, their growth is just beginning. According to Wall Street's consensus estimate, the following fourgrowth stocks are expected to see their sales climb by 306% to as much as 658% by 2024.</p><p><blockquote>但对于一些增压公司来说，它们的增长才刚刚开始。根据华尔街的普遍估计，到2024年，以下四只成长型股票的销售额预计将增长306%，达到658%。</blockquote></p><p> Redfin: Implied sales growth of 306% by 2024</p><p><blockquote>Redfin：到2024年隐含销售额增长306%</blockquote></p><p> One of the most profound growth stories over the next four years should be technology-driven real estate company <b>Redfin</b>(NASDAQ:RDFN). Last year, the company managed $886 million in revenue. But according to Wall Street, it'll be knocking on the door of $3.6 billion by the time 2024 rolls around.</p><p><blockquote>未来四年最深刻的增长故事之一应该是技术驱动的房地产公司<b>Redfin</b>（纳斯达克：RDFN）。去年，该公司管理的收入为8.86亿美元。但据华尔街报道，到2024年，它将敲开36亿美元的大门。</blockquote></p><p> There's no denying that Redfin has benefited from historically low mortgage rates. But eventually, mortgage rates will rise, and a seemingly spoiled group of prospective buyers will have to cope with rates of 4% or even 5% for 30-year mortgages. Yet even with higher mortgage rates, Redfinlooks poised to succeed.</p><p><blockquote>不可否认，Redfin受益于历史低位的抵押贷款利率。但最终，抵押贷款利率将会上升，一群看似被宠坏的潜在买家将不得不应对4%甚至5%的30年期抵押贷款利率。然而，即使抵押贷款利率较高，Redfin看起来也有望取得成功。</blockquote></p><p> One of the bigger differentiating factors for the company are thecost savings it brings to the table. Traditional real estate companies charge 2.5% to 3% to represent a buyer or seller. Meanwhile, Redfin charges either 1% or 1.5% to act as an agent for its clients.</p><p><blockquote>该公司更大的差异化因素之一是它带来的成本节约。传统房地产公司代表买方或卖方收取2.5%至3%的费用。与此同时，Redfin收取1%或1.5%的费用作为其客户的代理。</blockquote></p><p> This up to 2 percentage-point difference might sound nominally small, but it can easily top $7,000 in cost savings for a seller when we're talking about median-priced existing home sales. As long as economic or pandemic worries persist, the savings Redfin provides should remain in focus.</p><p><blockquote>这种高达2个百分点的差异名义上听起来可能很小，但当我们谈论中位价现房销售时，它可以轻松为卖家节省7,000美元的成本。只要经济或大流行担忧持续存在，Redfin提供的储蓄就应该继续成为焦点。</blockquote></p><p> Furthermore, Redfinprovides personalization that traditional real estate firms don't offer. As an example, Redfin rolled out 3D and virtual tours during the pandemic to keep the hamster on the wheel, so to speak. It also offers its Redfin Now purchasing services in select cities around the country. This service buys homes from sellers in cash, which removes the hassles and haggling that typically accompanies the home-selling process.</p><p><blockquote>此外，Redfin提供了传统房地产公司无法提供的个性化服务。举个例子，Redfin在疫情期间推出了3D和虚拟旅游，可以说是让仓鼠留在方向盘上。它还在全国特定城市提供Redfin Now购买服务。这项服务以现金从卖家那里购买房屋，消除了房屋销售过程中通常伴随的麻烦和讨价还价。</blockquote></p><p> With Redfin heavily reinvesting in its operations, it could be a couple of years before the company turns the corner to recurring profitability. However, sales growth won't demonstrably slow anytime soon.</p><p><blockquote>随着Redfin对其运营进行大量再投资，该公司可能需要几年时间才能实现经常性盈利。然而，销售增长不会很快明显放缓。</blockquote></p><p> Trulieve Cannabis: Implied sales growth of 344% by 2024</p><p><blockquote>Trulieve Cannabis：到2024年隐含销售额增长344%</blockquote></p><p> U.S.-based marijuana stocks are another source of supercharged growth over the coming four years. Perhaps no cannabis stock will deliver more eye-popping nominal sales growth than multistate operator (MSO)<b>Trulieve Cannabis</b>(OTC:TCNNF). Between 2020 and 2024, full-year sales are expected to climb from $521.5 million to about $2.32 billion.</p><p><blockquote>美国大麻股票是未来四年强劲增长的另一个来源。也许没有任何大麻股票能比多州运营商(MSO)带来更令人瞠目结舌的名义销售增长<b>Trulieve大麻</b>（场外交易代码：TCNNF）。2020年至2024年间，全年销售额预计将从5.215亿美元攀升至约23.2亿美元。</blockquote></p><p> To quickly get a big concern out of the way, federal legalization isn't necessary for pot stocks to thrive in the United States. We've witnessed 36 states legalize marijuana in some capacity, and the Justice Department is maintaining a hands-off approach. That's a recipe for high-quality MSOs to succeed.</p><p><blockquote>为了迅速解决一个大问题，联邦合法化并不是大麻股票在美国蓬勃发展的必要条件。我们已经见证了36个州以某种方式将大麻合法化，而司法部正在保持不干涉的态度。这是高质量MSO成功的秘诀。</blockquote></p><p> What's made Trulieve such a unique company is its laser focus on the Florida market. Whereas most MSOs have been stretching themselves thin in an attempt to establish a presence in as many legalized states as possible, Trulieve has opened 100 dispensaries in the Sunshine State. Saturating the medical marijuana-legal Florida market has allowed the company to keep its marketing costs down while effectively building up its brands. It now controls about half the state's dried flower and oils share and has been profitable on a recurring basis for more than three years.</p><p><blockquote>Trulieve之所以成为一家如此独特的公司，是因为它专注于佛罗里达市场。尽管大多数MSO都在竭尽全力试图在尽可能多的合法化州建立业务，但Trulieve已经在阳光州开设了100家药房。医用大麻合法的佛罗里达州市场饱和，使该公司能够在有效建立品牌的同时降低营销成本。它现在控制着该州大约一半的干花和油份额，并且已经连续盈利三年多了。</blockquote></p><p> The next phase of growth for Trulieve will be inorganic. It recently closed an all-stock deal to acquire MSO Harvest Health & Recreation. While Harvest Health had a five-state focus, the allure of this acquisition is Harvest's leading position (15 dispensaries) in its home state of Arizona. The Grand Canyon State legalized recreational weed in November and commenced sales two months later. Trulieve could very well become a runaway leader in Arizona and show shareholders the green.</p><p><blockquote>Trulieve的下一个增长阶段将是无机的。它最近完成了收购MSO Harvest Health&Recreation的全股票交易。虽然Harvest Health专注于五个州，但此次收购的吸引力在于Harvest在其家乡亚利桑那州的领先地位（15家药房）。大峡谷州在11月将娱乐性大麻合法化，并在两个月后开始销售。Trulieve很可能成为亚利桑那州的失控领导者，并向股东展示绿色。</blockquote></p><p> Novavax: Implied sales growth of 658% by 2024</p><p><blockquote>Novavax：到2024年隐含销售额增长658%</blockquote></p><p> It's not surprising to find supercharged growth potential amongbiotech stocks. Going from non-recurring revenue to recurring sales following a first drug approval can lead to a huge percentage surge in sales.</p><p><blockquote>生物科技股的强劲增长潜力并不奇怪。第一个药物获得批准后，从非经常性收入转向经常性销售可能会导致销售额大幅增长。</blockquote></p><p> That's what's expected to happen with <b>Novavax</b>(NASDAQ:NVAX). In 2020, the company recorded almost $476 million in full-year sales. But by 2024, Wall Street's consensus has Novavax pegged for a hair above $3.6 billion in revenue.</p><p><blockquote>这就是预期会发生的事情<b>Novavax</b>（纳斯达克：NVAX）。2020年，该公司全年销售额近4.76亿美元。但华尔街一致认为，到2024年，Novavax的收入将略高于36亿美元。</blockquote></p><p> For the time being, Novavax is a clinical-stage company -- but that seems destined to change.</p><p><blockquote>目前，Novavax是一家处于临床阶段的公司，但这种情况似乎注定会改变。</blockquote></p><p></p><p> The company's leading vaccine candidate is NVX-CoV2373, a treatment for the coronavirus disease 2019 (COVID-19). This vaccine has been through two large-scale, late-stage studies that produced overall vaccine efficacy (VE) of 89.7% (in the U.K.) and 90.4% (in the U.S. and Mexico). While initial VE is just one aspect of the COVID-19 vaccine, Novavax offers a solution that appears to handily outpace <b>Johnson & Johnson</b> and <b>AstraZeneca</b> in initial VE. In other words, it could slide right in as the global No. 3 COVID-19 vaccine if granted emergency-use authorization.</p><p><blockquote>该公司领先的候选疫苗是NVX-CoV2373，一种治疗冠状病毒疾病2019（COVID-19）的药物。该疫苗已经通过了两项大规模的后期研究，总体疫苗效力(VE)分别为89.7%（在英国）和90.4%（在美国和墨西哥）。虽然初始VE只是COVID-19疫苗的一个方面，但Novavax提供的解决方案似乎可以轻松超越<b>强生公司</b>和<b>阿斯利康</b>在初始VE中。换句话说，如果获得紧急使用授权，它可能会成为全球第三大COVID-19疫苗。</blockquote></p><p> Additionally, Novavax could set itself apart from the competition by producing combination vaccines, such as COVID-19 and influenza. The company's vaccine-development platform is designed in such a way that it can potentially beat other large drugmakers to market with combination vaccinations or variant-specific boosters.</p><p><blockquote>此外，Novavax可以通过生产COVID-19和流感等联合疫苗在竞争中脱颖而出。该公司的疫苗开发平台的设计方式是，它有可能击败其他大型制药商，将联合疫苗或变异特异性加强剂推向市场。</blockquote></p><p> Among COVID-19 stocks, Novavax remains the most intriguing, in my view.</p><p><blockquote>在我看来，在COVID-19股票中，Novavax仍然是最有趣的。</blockquote></p><p> fuboTV: Implied sales growth of 582% by 2024</p><p><blockquote>fuboTV：到2024年隐含销售额增长582%</blockquote></p><p> The fourth and final supercharged growth stock is streaming-television provider <b>fuboTV</b>(NYSE:FUBO). After the company delivered $261.5 million in full-year sales in 2020, Wall Street is expecting sales to increase to around $1.78 billion in 2024. That's a cool 582% improvement.</p><p><blockquote>第四只也是最后一只强劲增长的股票是流媒体电视提供商<b>富波电视</b>（纽约证券交易所代码：FUBO）。在该公司2020年全年销售额达到2.615亿美元后，华尔街预计2024年销售额将增至17.8亿美元左右。这是一个很酷的582%的改进。</blockquote></p><p> FuboTV is aiming to capitalize on consumers' distaste of traditional cable, satellite, and telcoTV. A report from NScreen Media shows that over 21 million fewer households had one of these traditional content services in the first quarter of 2021, compared to the same quarter four years earlier. At the same time, the number of households without a traditional cable, satellite, or telcoTV has more than tripled between 2014 and Q1 2021. People are clearly dissatisfied with the lack of choice from traditional cable and satellite providers, and they're unhappy with the high service costs.</p><p><blockquote>FuboTV的目标是利用消费者对传统有线、卫星和电信电视的厌恶。NScreen Media的一份报告显示，与四年前的同一季度相比，2021年第一季度拥有这些传统内容服务的家庭减少了2100多万户。与此同时，2014年至Q1 2021年间，没有传统有线电视、卫星电视或电信电视的家庭数量增加了两倍多。人们显然对传统有线电视和卫星电视提供商缺乏选择感到不满，也对高昂的服务成本感到不满。</blockquote></p><p> For fuboTV, it's all about appealing to consumers who want streamable, live sporting events. Although it offers news and entertainment content, too, the company's core customer, for the moment, is a sports fanatic who wants to cut their content costs. As of June, the company had 682,000 subscribers, which is more than double what it had last year, but still represents a very small figure.</p><p><blockquote>对于fuboTV来说，这一切都是为了吸引想要流媒体直播体育赛事的消费者。尽管它也提供新闻和娱乐内容，但该公司目前的核心客户是希望削减内容成本的体育迷。截至6月，该公司拥有682,000名订户，是去年的两倍多，但仍是一个非常小的数字。</blockquote></p><p> The big question for fuboTV is what'll allow it to separate from the competition. The answer to that question might be sports betting. The company has recently been granted mobile sports-betting licenses in a handful of states, which could provide a tangible lure to the platform.</p><p><blockquote>对于fuboTV来说，最大的问题是什么能让它从竞争中脱颖而出。这个问题的答案可能是体育博彩。该公司最近在几个州获得了移动体育博彩许可证，这可能会给该平台带来切实的吸引力。</blockquote></p><p> For now, fuboTV is losing money hand over fist as it attempts to build up its brand. But if it can find a truly differentiating factor in the streaming space, it could offer long-term appeal.</p><p><blockquote>目前，fuboTV在试图建立自己的品牌时正在大幅亏损。但如果它能在流媒体领域找到真正的差异化因素，它可能会提供长期吸引力。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/21/4-growth-stocks-increase-sales-306-to-658-by-2024/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RDFN":"Redfin Corp","FUBO":"fuboTV Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/21/4-growth-stocks-increase-sales-306-to-658-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173506176","content_text":"If there's been one standout group of stocks since the end of the Great Recession in 2009, it's growth stocks. The combination of historically low lending rates and the Federal Reserve's ongoing quantitative-easing measures have made cheap capital abundant for borrowing purposes.\nBut for some supercharged companies, their growth is just beginning. According to Wall Street's consensus estimate, the following fourgrowth stocks are expected to see their sales climb by 306% to as much as 658% by 2024.\nRedfin: Implied sales growth of 306% by 2024\nOne of the most profound growth stories over the next four years should be technology-driven real estate company Redfin(NASDAQ:RDFN). Last year, the company managed $886 million in revenue. But according to Wall Street, it'll be knocking on the door of $3.6 billion by the time 2024 rolls around.\nThere's no denying that Redfin has benefited from historically low mortgage rates. But eventually, mortgage rates will rise, and a seemingly spoiled group of prospective buyers will have to cope with rates of 4% or even 5% for 30-year mortgages. Yet even with higher mortgage rates, Redfinlooks poised to succeed.\nOne of the bigger differentiating factors for the company are thecost savings it brings to the table. Traditional real estate companies charge 2.5% to 3% to represent a buyer or seller. Meanwhile, Redfin charges either 1% or 1.5% to act as an agent for its clients.\nThis up to 2 percentage-point difference might sound nominally small, but it can easily top $7,000 in cost savings for a seller when we're talking about median-priced existing home sales. As long as economic or pandemic worries persist, the savings Redfin provides should remain in focus.\nFurthermore, Redfinprovides personalization that traditional real estate firms don't offer. As an example, Redfin rolled out 3D and virtual tours during the pandemic to keep the hamster on the wheel, so to speak. It also offers its Redfin Now purchasing services in select cities around the country. This service buys homes from sellers in cash, which removes the hassles and haggling that typically accompanies the home-selling process.\nWith Redfin heavily reinvesting in its operations, it could be a couple of years before the company turns the corner to recurring profitability. However, sales growth won't demonstrably slow anytime soon.\nTrulieve Cannabis: Implied sales growth of 344% by 2024\nU.S.-based marijuana stocks are another source of supercharged growth over the coming four years. Perhaps no cannabis stock will deliver more eye-popping nominal sales growth than multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF). Between 2020 and 2024, full-year sales are expected to climb from $521.5 million to about $2.32 billion.\nTo quickly get a big concern out of the way, federal legalization isn't necessary for pot stocks to thrive in the United States. We've witnessed 36 states legalize marijuana in some capacity, and the Justice Department is maintaining a hands-off approach. That's a recipe for high-quality MSOs to succeed.\nWhat's made Trulieve such a unique company is its laser focus on the Florida market. Whereas most MSOs have been stretching themselves thin in an attempt to establish a presence in as many legalized states as possible, Trulieve has opened 100 dispensaries in the Sunshine State. Saturating the medical marijuana-legal Florida market has allowed the company to keep its marketing costs down while effectively building up its brands. It now controls about half the state's dried flower and oils share and has been profitable on a recurring basis for more than three years.\nThe next phase of growth for Trulieve will be inorganic. It recently closed an all-stock deal to acquire MSO Harvest Health & Recreation. While Harvest Health had a five-state focus, the allure of this acquisition is Harvest's leading position (15 dispensaries) in its home state of Arizona. The Grand Canyon State legalized recreational weed in November and commenced sales two months later. Trulieve could very well become a runaway leader in Arizona and show shareholders the green.\nNovavax: Implied sales growth of 658% by 2024\nIt's not surprising to find supercharged growth potential amongbiotech stocks. Going from non-recurring revenue to recurring sales following a first drug approval can lead to a huge percentage surge in sales.\nThat's what's expected to happen with Novavax(NASDAQ:NVAX). In 2020, the company recorded almost $476 million in full-year sales. But by 2024, Wall Street's consensus has Novavax pegged for a hair above $3.6 billion in revenue.\nFor the time being, Novavax is a clinical-stage company -- but that seems destined to change.\nThe company's leading vaccine candidate is NVX-CoV2373, a treatment for the coronavirus disease 2019 (COVID-19). This vaccine has been through two large-scale, late-stage studies that produced overall vaccine efficacy (VE) of 89.7% (in the U.K.) and 90.4% (in the U.S. and Mexico). While initial VE is just one aspect of the COVID-19 vaccine, Novavax offers a solution that appears to handily outpace Johnson & Johnson and AstraZeneca in initial VE. In other words, it could slide right in as the global No. 3 COVID-19 vaccine if granted emergency-use authorization.\nAdditionally, Novavax could set itself apart from the competition by producing combination vaccines, such as COVID-19 and influenza. The company's vaccine-development platform is designed in such a way that it can potentially beat other large drugmakers to market with combination vaccinations or variant-specific boosters.\nAmong COVID-19 stocks, Novavax remains the most intriguing, in my view.\nfuboTV: Implied sales growth of 582% by 2024\nThe fourth and final supercharged growth stock is streaming-television provider fuboTV(NYSE:FUBO). After the company delivered $261.5 million in full-year sales in 2020, Wall Street is expecting sales to increase to around $1.78 billion in 2024. That's a cool 582% improvement.\nFuboTV is aiming to capitalize on consumers' distaste of traditional cable, satellite, and telcoTV. A report from NScreen Media shows that over 21 million fewer households had one of these traditional content services in the first quarter of 2021, compared to the same quarter four years earlier. At the same time, the number of households without a traditional cable, satellite, or telcoTV has more than tripled between 2014 and Q1 2021. People are clearly dissatisfied with the lack of choice from traditional cable and satellite providers, and they're unhappy with the high service costs.\nFor fuboTV, it's all about appealing to consumers who want streamable, live sporting events. Although it offers news and entertainment content, too, the company's core customer, for the moment, is a sports fanatic who wants to cut their content costs. As of June, the company had 682,000 subscribers, which is more than double what it had last year, but still represents a very small figure.\nThe big question for fuboTV is what'll allow it to separate from the competition. The answer to that question might be sports betting. The company has recently been granted mobile sports-betting licenses in a handful of states, which could provide a tangible lure to the platform.\nFor now, fuboTV is losing money hand over fist as it attempts to build up its brand. But if it can find a truly differentiating factor in the streaming space, it could offer long-term appeal.","news_type":1,"symbols_score_info":{"NVAX":0.9,"FUBO":0.9,"RDFN":0.9}},"isVote":1,"tweetType":1,"viewCount":3087,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["FUBO"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":24,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/851099558"}
精彩评论